A Phase 1 interventional study of Misoprostol and Oxytocin in Post Partum Hemorrhage, sponsored by Hormozgan University of Medical Sciences. Completed at 1 site in Iran, Islamic Republic of. Open to female participants aged 10 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-26.
Sponsored by Hormozgan University of Medical Sciences · Phase 1, Interventional, and Prevention
Post partum Hemorrhage (PPH) is one of three main causes of death in pregnant women. Oxytocin is widely used for prevention of PPH. Some studies suggested misoprostol as an alternative treatment when Oxytocin isn't available. The aim of this study is to compare the safety and efficacy of Oxytocin and misoprostol for prevention of PPH.
In a double blind randomized controlled trial 400 pregnant women who has vaginal delivery at Shariati hospital are assigned into two groups either to receive 20 unite oxytocin in 1000cc ringer and 2 placebo tablet or 400mcg oral misoprostol and 2cc normal saline in 1000cc ringer.
445 studies on the registry are indexed under Postpartum Hemorrhage; 75 are open to participants now.
This study's planned enrollment of 400 is above the median of 148 across 340 interventional studies indexed under Postpartum Hemorrhage.
Browse Postpartum Hemorrhage studies →Hormozgan University of Medical Sciences is the lead sponsor of 23 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
400µg oral misoprostol
Drug: Misoprostol
20 IU oxytocin
Drug: Oxytocin
400µg oral misoprostol
Also known as: Cytotec
20 IU Oxytocin
Also known as: Syntocinon
Amount of bleeding
within 1 hours after delivery
Time frame: 1 hour
Hemoglobin decrease
Time frame: 24 hours
Hematocrite decrease
Time frame: 24 hours
Side effects
Diarrhea, Vommiting, Fever, Chills
Time frame: 24 hours
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hormozgan University of Medical Sciences